RedHill Biopharma Ltd. (RDHL)
USD 2.27
(-5.84%)
USD 2.27
(-5.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.97 Million USD | -89.88% |
| 2022 | 207.27 Million USD | 20.29% |
| 2021 | 172.31 Million USD | 3.57% |
| 2020 | 166.37 Million USD | 1080.23% |
| 2019 | 14.09 Million USD | 25.59% |
| 2018 | 11.22 Million USD | -8.58% |
| 2017 | 12.27 Million USD | 6.66% |
| 2016 | 11.51 Million USD | 70.51% |
| 2015 | 6.75 Million USD | 75.58% |
| 2014 | 3.84 Million USD | 59.21% |
| 2013 | 2.41 Million USD | 124.03% |
| 2012 | 1.07 Million USD | -22.94% |
| 2011 | 1.39 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 20.97 Million USD | -89.88% |
| 2023 Q2 | 31.56 Million USD | -44.46% |
| 2023 Q1 | 56.83 Million USD | -72.58% |
| 2022 Q1 | 172.29 Million USD | -0.01% |
| 2022 FY | 207.27 Million USD | 20.29% |
| 2022 Q4 | 207.27 Million USD | 1.99% |
| 2022 Q3 | 203.21 Million USD | 12.96% |
| 2022 Q2 | 179.9 Million USD | 4.42% |
| 2021 Q1 | 167.08 Million USD | 0.42% |
| 2021 Q4 | 172.31 Million USD | -1.42% |
| 2021 Q3 | 174.78 Million USD | 0.4% |
| 2021 FY | 172.31 Million USD | 3.57% |
| 2021 Q2 | 174.09 Million USD | 4.2% |
| 2020 Q3 | 140.23 Million USD | 6.41% |
| 2020 Q4 | 166.37 Million USD | 18.64% |
| 2020 Q1 | 99.83 Million USD | 608.19% |
| 2020 FY | 166.37 Million USD | 1080.23% |
| 2020 Q2 | 131.78 Million USD | 32.0% |
| 2019 Q2 | 17.79 Million USD | 9.42% |
| 2019 Q3 | 17.39 Million USD | -2.23% |
| 2019 Q4 | 14.09 Million USD | -18.95% |
| 2019 FY | 14.09 Million USD | 25.59% |
| 2019 Q1 | 16.25 Million USD | 44.85% |
| 2018 FY | 11.22 Million USD | -8.58% |
| 2018 Q4 | 11.22 Million USD | -17.05% |
| 2018 Q3 | 13.53 Million USD | 13.32% |
| 2018 Q2 | 11.94 Million USD | 18.2% |
| 2018 Q1 | 10.1 Million USD | -17.71% |
| 2017 Q1 | 10.65 Million USD | -7.4% |
| 2017 FY | 12.27 Million USD | 6.66% |
| 2017 Q4 | 12.27 Million USD | -24.85% |
| 2017 Q3 | 16.33 Million USD | 23.94% |
| 2017 Q2 | 13.18 Million USD | 23.67% |
| 2016 Q1 | 6.61 Million USD | -1.97% |
| 2016 FY | 11.51 Million USD | 70.51% |
| 2016 Q4 | 11.51 Million USD | 37.12% |
| 2016 Q3 | 8.39 Million USD | 15.36% |
| 2016 Q2 | 7.27 Million USD | 9.96% |
| 2015 FY | 6.75 Million USD | 75.58% |
| 2015 Q4 | 6.75 Million USD | 21.68% |
| 2015 Q3 | 5.54 Million USD | -17.9% |
| 2015 Q2 | 6.75 Million USD | -7.93% |
| 2015 Q1 | 7.34 Million USD | 90.9% |
| 2014 Q1 | 3.53 Million USD | 46.34% |
| 2014 FY | 3.84 Million USD | 59.21% |
| 2014 Q4 | 3.84 Million USD | -11.61% |
| 2014 Q3 | 4.35 Million USD | -21.88% |
| 2014 Q2 | 5.56 Million USD | 57.56% |
| 2013 Q4 | 2.41 Million USD | 25.52% |
| 2013 FY | 2.41 Million USD | 124.03% |
| 2013 Q2 | 1.76 Million USD | 32.31% |
| 2013 Q1 | 1.33 Million USD | 23.47% |
| 2013 Q3 | 1.92 Million USD | 9.26% |
| 2012 FY | 1.07 Million USD | -22.94% |
| 2012 Q3 | 1.83 Million USD | 0.0% |
| 2012 Q4 | 1.07 Million USD | -41.13% |
| 2011 Q4 | 1.39 Million USD | 0.0% |
| 2011 FY | 1.39 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 97.787% |
| Embecta Corp. | 2.03 Billion USD | 98.97% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 95.552% |
| Dynavax Technologies Corporation | 375.02 Million USD | 94.406% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 96.825% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 97.021% |
| PainReform Ltd. | 2.69 Million USD | -679.566% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 87.201% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -241.686% |
| SCYNEXIS, Inc. | 55.45 Million USD | 62.167% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -128.107% |
| Cosmos Health Inc. | 30.25 Million USD | 30.657% |
| Journey Medical Corporation | 56.49 Million USD | 62.87% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -241.686% |
| Safety Shot Inc | 3.89 Million USD | -439.0% |
| Alpha Teknova, Inc. | 38.55 Million USD | 45.583% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 84.673% |
| Bright Green Corporation | 6.43 Million USD | -225.843% |
| Procaps Group, S.A. | 462.06 Million USD | 95.46% |
| Theratechnologies Inc. | 98.63 Million USD | 78.732% |
| Harrow Health, Inc. | 241.75 Million USD | 91.322% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -139.586% |
| Biofrontera Inc. | 23.13 Million USD | 9.339% |
| DURECT Corporation | 30.4 Million USD | 31.007% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 95.696% |
| Cronos Group Inc. | 43.73 Million USD | 52.035% |
| OptiNose, Inc. | 194.33 Million USD | 89.205% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 97.433% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 56.697% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 88.433% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -456.134% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 60.054% |
| Radius Health, Inc. | 804.29 Million USD | 97.392% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -52.52% |
| ProPhase Labs, Inc. | 42.54 Million USD | 50.691% |
| Phibro Animal Health Corporation | 725.54 Million USD | 97.109% |
| Procaps Group S.A. | 462.06 Million USD | 95.46% |
| Alvotech | 1.88 Billion USD | 98.886% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -49.609% |
| Viatris Inc. | 27.21 Billion USD | 99.923% |
| Rockwell Medical, Inc. | 30.88 Million USD | 32.07% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 76.789% |
| SIGA Technologies, Inc. | 57.97 Million USD | 63.817% |
| Tilray Brands, Inc. | 892.11 Million USD | 97.649% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 90.456% |
| Shineco, Inc. | 47.6 Million USD | 55.93% |
| PetIQ, Inc. | 645.22 Million USD | 96.749% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -9456.709% |
| Incannex Healthcare Limited | 5.83 Million USD | -259.831% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 97.942% |
| Alimera Sciences, Inc. | 107.35 Million USD | 80.459% |
| Silver Spike Investment Corp. | 3 Million USD | -596.987% |
| Assertio Holdings, Inc. | 148.41 Million USD | 85.865% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1006.462% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 1.584% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -198.578% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -147.077% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 87.901% |
| Hempacco Co., Inc. | 18.82 Million USD | -11.453% |
| Talphera, Inc. | 6.29 Million USD | -233.515% |
| Alvotech | 1.88 Billion USD | 98.886% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 87.846% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 97.488% |
| Currenc Group, Inc. | 177.67 Million USD | 88.193% |
| Kamada Ltd. | 109.96 Million USD | 80.923% |
| Indivior PLC | 1.95 Billion USD | 98.925% |
| Evoke Pharma, Inc. | 9.64 Million USD | -117.433% |
| Flora Growth Corp. | 17.22 Million USD | -21.81% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -147.077% |
| Evolus, Inc. | 209.68 Million USD | 89.996% |
| HUTCHMED (China) Limited | 536.38 Million USD | 96.089% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 97.598% |
| Akanda Corp. | 12.66 Million USD | -65.588% |